PropertyValue
?:abstract
  • BACKGROUND: Due to the lack of proven therapies, we evaluated the effects of early administration of tocilizumab for COVID-19. By inhibition of the IL-6 ... »more»
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1186/s12879-020-05701-4
?:journal
  • BMC_Infect_Dis
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/5b3748e977913a37b3895369d0a5d705cbb9fe82.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7755065.xml.json
?:pmcid
?:pmid
?:pmid
  • 33353546.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Medline; PMC
?:title
  • Effects of Tocilizumab in COVID-19 patients: a cohort study
?:type
?:year
  • 2020-12-22

Metadata

Anon_0  
expand all